Patients with primary sclerosing cholangitis with and without end-stage liver disease have similar outcomes after liver transplantation

Table 3 Univariate and multivariate analyses of graft failure risk factors

Characteristic	Univariable				Multivariable
	n	HR	95%CI	P value	HR	95%CI	P value
Age at LT	131	0.98	0.94-1.01	0.2	0.97	0.92-1.02	0.2
Sex	131	-	-	-	-	-	-
Female	-	-	-	-	-	-	-
Male	-	1.69	0.56-5.09	0.3	2.67	0.61-11.7	0.2
Overlap PSC/AIH	131	1.53	0.55-4.29	0.4	4.07	0.93-17.9	0.063
IBD before LT	131	0.77	0.31-1.93	0.6	1.28	0.39-4.15	0.7
Liver cirrhosis	131	1.33	0.39-4.55	0.7	1.34	0.29-6.18	0.7
Decompensation of liver cirrhosis	131	1.02	0.42-2.48	> 0.9	0.69	0.17-2.77	0.6
Child-Pugh score prior to LT	131	1.06	0.83-1.36	0.6	-	-	-
MELD prior to LT	131	1.01	0.93-1.10	0.8	0.95	0.82-1.10	0.5
End-stage liver disease indication	131	0.93	0.39-2.25	0.9	1.73	0.36-8.38	0.5
Split or reduced graft	131	1.55	0.20-12.2	0.7	4.76	0.46-48.8	0.2
Donor type	131	-	-	-	-	-	-
DBD-ECD	-	-	-	-	-	-	-
DBD-SCD	-	0.81	0.22-2.90	0.7	2.29	0.45-11.5	0.3
Donor-recipient sex missmatch	131	1.22	0.50-2.96	0.7	2.21	0.63-7.80	0.2
Cyclosporine	131	0.54	0.17-1.76	0.3	0.21	0.04-1.06	0.059
Duct-to-duct anastomosis	131	0.76	0.25-2.36	0.6	0.58	0.14-2.46	0.5
Episode of ACR	131	1.51	0.62-3.72	0.4	1.36	0.38-4.81	0.6
Multiple episodes of ACR	131	3.48	1.32-9.14	0.011	4.93	1.22-19.9	0.025
CMV infection	131	2.14	0.87-5.24	0.10	2.51	0.77-8.19	0.13
Length of hospitalization	131	1.02	1.00-1.04	0.029	1.04	1.01-1.06	0.001

ACR: Acute cellular rejection; AIH: Autoimmune hepatitis; CI: Confidence interval; CMV: Cytomegalovirus; DBD: Donation after brain death; ECD: Expanded criteria donor; HR: Hazard ratio; IBD: Inflammatory bowel disease; LT: Liver transplantation; MELD: Model for end-stage liver disease; PSC: Primary sclerosing cholangitis; SCD: Standard criteria donor.